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Abstract A cluster of manuscripts in this issue of the
Journal highlights a lack of selectivity of 49 antibodies
against 19 subtypes of α1- and β-adrenoceptors, muscarinic,
dopamine and galanin receptors as well as vanilloid
(TRPV1) receptors. Taken together these data demonstrate
that lack of selectivity appears to be the rule rather than the
exception for antibodies against G-protein-coupled and
perhaps also other receptors. Thus, the previously often
applied validation of such antibodies by the disappearance
of staining in the presence of blocking peptide, i.e. the
antigen against which the antibody was raised, alone is
insufficient to demonstrate specificity. We propose that
receptor antibodies should be validated by at least one of
the following techniques: a) disappearance of staining in
knock-out animals of the target receptor, b) reduction of
staining upon knock-down approaches such as siRNA
treatment, c) selectivity of staining in immunoblots or
immunocytochemistry for the target receptor vs. related
subtypes when expressed in the same cell line and/or d)
antibodies raised against multiple distinct epitopes of a
receptor yielding very similar staining patterns. Other issues
of consideration to obtain reliable results based on receptor
antibodies in applications such as immunohistochemistry or
immunoblotting are also being discussed.
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G-protein-coupled receptors (GPCR) are important regula-
tors of cellular function (Penn 2008). They can be
subdivided into classes, families and individual subtypes.
Assigning specific functions to a given GPCR often
requires determining which subtype is expressed in a
specific cell. As GPCR mRNA and protein expression at
the cell surface do not necessarily correlate, detection at the
protein level is frequently required. GPCR protein detection
may also be helpful to identify which cell type within a
tissue expresses a given receptor and/or in which subcellu-
lar component receptors are found. Moreover, the expres-
sion density of GPCR at the cell surface is not a static entity
but rather dynamically regulated by a variety of physiolog-
ical and pathophysiological conditions as well as drug
treatment (Insel et al. 2007). A better understanding of such
regulation also often requires specific quantification of
expression at the protein level. While genetically modified,
e.g. HA- or His-tagged receptors, can easily be detected
using antibodies against the respective tag (Jongsma et al.
2007), such detection is not applicable to endogenous
receptors. Hence, the detection of native GPCR protein
typically relies on the use of either specific radioligands,
otherwise labelled ligands or antibodies. While radioligands
have been extremely useful for studies of many GPCR
(Myslivecek et al. 2008; Myslivecek et al. 2007) and
continue to emerge, e.g. for nociceptin/orphanin FQ
receptors (Ibba et al. 2008), suitable radioligands are
missing for many other GPCR, e.g. for β3-adrenoceptors
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(Vrydag and Michel 2007) or free fatty acid receptors
(Tanaka et al. 2008). Therefore, antibodies are the only
available option to detect many GPCR, and numerous such
antibodies are commercially available from various suppliers.
If these would be reliable, they would be highly important
tools for pharmacological studies. Technical approaches for
the generation and validation of receptor antibodies have
been reviewed comprehensively (Gupta and Devi 2006;
Mackrill 2004).
Doubts about the usefulness of antibodies against GPCR
(O’Connell et al. 2006; Pradidarcheep et al. 2008; Rhodes
and Trimmer 2006), receptors from the ligand-gated ion
channel family (Herber et al. 2004) or transmitter trans-
porters (Chen et al. 2004) have been raised in the past and
have even led to the retraction of papers (Hawes and
Picciotto 2005). However, these reports have largely been
thought to represent isolated cases and did not raise more
fundamental questions about the use of receptor antibodies.
Hence, receptor antibodies continue to be used widely. In
this issue of the Journal, seven groups of investigators
report a lack of selectivity of a large number of receptor
antibodies for the claimed target receptor. This includes
antibodies against subtypes of α1-adrenoceptors (Jensen
et al. 2009), β-adrenoceptors (Hamdani and van der Velden
2009; Pradidarcheep et al. 2009), dopamine receptors
(Bodei et al. 2009), muscarinic receptors (Jositsch et al.
2009; Pradidarcheep et al. 2009), and galanin receptors (Lu
and Bartfai 2009). An additional report shows similar
problems with antibodies against receptors from the family
of ligand-gated ion channels, specifically the TRPV1
receptors (Everaerts et al. 2009), although other antibodies
directed against these receptors apparently are selective by
hard criteria (Charrua et al. 2009). In total, 49 antisera
against 19 distinct receptors have been tested in those
studies, 10 of which were tested by more than one group of
investigators; in many cases multiple antibodies were
investigated per receptor. However, none of them was
found to be selective. Taken together, these reports suggest
that a lack of selectivity of GPCR and perhaps other
receptor antibodies is the rule rather than the exception. In
the following we will discuss why so many GPCR
antibodies lack selectivity and what we consider to be
reliable criteria to demonstrate the specificity of receptor
antibodies.
Why do so many GPCR antibodies lack selectivity?
One possible explanation is that subtypes of a given GPCR
typically have high degrees of homology and hence
antibodies may easily recognize other subtypes within the
same family. Indeed, one study reported here shows that
antibodies against either β2- or β3-adrenoceptors recognize
rather similar band patterns on immunoblots from cells
expressing any of the nine adrenoceptors subtypes
(Pradidarcheep et al. 2009). However, the problem appar-
ently goes well beyond the homology of closely related
GPCR subtypes. For example, airways express only the M2
and M3 subtype of muscarinic receptors (Michel and Parra
2008) but double-knock-out mice lacking both subtypes
still stained positive for M2 and M3 receptor antibodies
(Jositsch et al. 2009). Similarly, triple knock-out mice
lacking all three α1-adrenoceptor subtypes show similar
staining patters as wild-type mice (Jensen et al. 2009).
Thus, if lack of selectivity is due to structural similarity
between GPCR, this may extend beyond members of a
given family to the overall group. If that was true,
antibodies raised against less conserved regions of GPCR,
e.g. the N- or C-terminal tails may have a better chance for
selectivity. However, some findings in this issue of the
Journal demonstrate that N- and C-terminal-directed anti-
bodies similarly lack specificity as those directed against
more conserved receptor domains (Jensen et al. 2009;
Jositsch et al. 2009). Irrespective of such considerations,
these problems suggest that many previously published
data, including some in this Journal (Otsuka et al. 2008;
van Diepen et al. 2008), may require re-interpretation. This
shows that irrespective of a good explanation for the lack of
selectivity of many GPCR antibodies, it is important to
develop better criteria to accept an antibody as specific for
its target.
Criteria to demonstrate receptor antibody specificity
The problems with many existing antibodies necessitate
revisiting which criteria are acceptable to demonstrate
selectivity of an antibody for its claimed cognate receptor.
The criterion most often applied in the past is disappearance
of staining in the presence of blocking peptide, i.e. the
peptide against which the antiserum was raised. However,
the examples in this issue of the Journal demonstrate that
this is insufficient to demonstrate selectivity as almost all of
the tested antibodies had been claimed to be selective based
upon blocking peptide testing. A second soft criterion used
in the past is that antibodies against different subtypes of a
given receptor exhibit distinct staining patters in tissues.
However, studies with both knock-out mice (Everaerts et al.
2009; Jensen et al. 2009; Jositsch et al. 2009; Lu and
Bartfai 2009; Pradidarcheep et al. 2008) or immunoblots
comparing staining to cloned receptor subtypes (Bodei
et al. 2009; Hamdani and van der Velden 2009; Pradidarcheep
et al. 2009) demonstrate that this also is insufficient to prove
selectivity. Rather we propose that at least one of the
following four conditions must be met to consider an
antiserum to indeed be selective.
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Firstly, selectivity of an antibody is likely if its staining
disappears in immunohistochemical studies or immunoblots
of tissues from animals genetically engineered to lack that
receptor. Several studies demonstrate that many available
antibodies fail to meet this test (Everaerts et al. 2009;
Jensen et al. 2009; Jositsch et al. 2009; Lu and Bartfai
2009; Pradidarcheep et al. 2008). Secondly, animals or cell
lines can be treated with genetic tools to knock-down
expression of a given receptor, e.g. siRNA; if that leads to a
major reduction of staining by a given antibody, this also
constitutes reasonable evidence for its specificity. Thirdly,
studies with transfection of multiple subtypes of a given
receptor into the same host cell line in which the target
receptor but not the related subtypes yield positive staining
also can provide strong evidence for selectivity (Bodei et al.
2009; Hamdani and van der Velden 2009; Pradidarcheep
et al. 2009). Finally, in a more classical immunological
approach, it can be considered as reasonable evidence of
selectivity if multiple antibodies raised against different
epitopes of a GPCR, e.g. N-terminus, intracellular loop and
C-terminus, show a very similar staining pattern in
immunohistochemistry and/or immunoblotting. Of note,
with the possible exception of the third proposed option,
all of these criteria may also be applied to antibodies raised
against targets other than GPCR. A recent report demon-
strates an additional approach based on tagged receptors, in
which a GPCR antibody detects the same protein as the
antibody against the tag (Miyauchi et al. 2009); however,
this approach needs to be validated in further studies using
the hard criteria described above.
Additional considerations for the validation of receptor
antibodies
The apparent selectivity or lack thereof for a receptor
antibody may also depend on other factors. For example, in
immunohistochemical studies the recognition pattern of an
antiserum may depend on the protocols used for tissue
fixation (Jensen et al. 2009). Also, an antibody raised
against a recombinant protein or part of it might be highly
specific in immunohistochemistry, but is not able to detect
the protein after its threedimensional structure has been
destroyed, e.g. by solubilization in Laemmli buffer.
Selectivity data based upon immunoblots may be liable
to additional problems when used for other purposes. Thus,
even if a band of appropriate size is present only in extracts
of cells expressing the target receptor but not in those
expressing related subtypes, this does not necessarily
demonstrate the usefulness of such antibodies for immuno-
histochemistry. As immunohistochemistry relies on the idea
that all or at least most staining comes from the target
protein, staining of additional bands in immunoblots may
be a significant source of error when using the same
antiserum in immunohistochemistry. Thus, the number of
detected bands on an immunoblot may to a large degree
depend protein loading of the gel, and only antibodies
exhibiting immunoblot specificity over a wide range of
loading densities may have sufficient specificity for
immunohistochemistry. A variation of this idea is that an
antibody may exhibit “specificity” when tested on cell lines
with marked overexpression but not when much lower
physiological expression densities are assessed, i.e. has
poor sensitivity for its target receptor. This is particularly
true if evidence for specificity is based solely on the
presence of a band on immunoblots from overexpressing as
compared to mock-transfected cells.
Conclusions and future editorial policy
As a lack of selectivity appears to be the rule rather than
the exception with GPCR antibodies, the scientific
community should consider which requirements are
agreed upon to consider an antibody to have validated
selectivity for its claimed cognate receptor. To initiate
such discussion, we propose four criteria, of which at least
one should be fulfilled as reasonable evidence for
selectivity. At least for this Journal, this will become an
editorial policy for all manuscripts which use GPCR
antibodies. We additionally propose that similarly rigorous
validation approaches should also be applied to antibodies
against targets other than GPCR. Finally, the various
reports in this issue of the journal imply that lack of
selectivity of receptor antibodies is not a problem of one or
two specific commercial suppliers but rather appears to be
applicable to all antibody sources, both commercial and
academic. As the data in this issue of the journal raise more
questions than provide answers, the journal welcomes
scientific comments from the academic community and
commercial antibody suppliers with regard to strategies for
improved antibody selectivity and/or criteria to demonstrate
such selectivity.
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